From discovering resilience-first therapeutics to building the platform that generates them.

Since 2017, Sen-Jam has been discovering and developing therapeutics designed to resolve inflammation, restore balance, and preserve resilience. Today, we are transforming that proven discovery process into an AI-powered computational platform—enabling us to identify, develop, and scale resilience-first therapeutics faster than ever before.

We don't just develop drugs.

We're building the engine that discovers them.

Earlier intervention. Safer solutions. More complete inflammation resolution.

Designed to preserve resilience and extend healthspan.

Clinically validated. Built for scale.

THE ONE QUESTION THAT STARTED IT ALL

For decades, medicine divided health into diseases, symptoms, and specialties.

We became interested in what connected them.

In 2019, Jackie Iversen challenged the idea that the future of medicine would be built one disease at a time. Instead, because of the discoveries she was making as a visionary pharmacist, she proposed that the greatest opportunity lay in understanding the shared biology beneath them.

That insight became the foundation for Sen-Jam.

Over the next six years, it guided the discovery of a growing portfolio of therapeutics designed to resolve inflammation, restore balance, and preserve resilience.

Today, it powers our mission to decode the biology of resilience and translate it into the next generation of longevity therapeutics.

Not disease by disease.

Biology first.

LOSS OF RESILIENCE IS THE PROCESS. DISEASE IS THE OUTCOME.

Across aging, chronic disease, recovery, and human performance, a common biology is at work: inflammation.

Long before symptoms appear, resilience is already being lost.

Most medicine begins after dysfunction emerges—treating diseases once damage has already occurred.

We believe the greatest opportunity lies earlier.

By understanding and restoring the biological systems that preserve resilience, it may be possible to influence not just one condition, but many of the processes that shape how we age, recover, and maintain health over time.

Different conditions. Shared biology.

A new frontier for medicine.

INTRODUCING: THE INFLAMMATION ATLAS

From Biological Insight to Therapeutic Generation

Most drug discovery begins with disease.

Atlas begins with the biology beneath it.

Built on six years of therapeutic discovery and grounded in proprietary clinical data from 199 patients across two independent studies, the Inflammation Atlas is Sen-Jam's AI-powered computational platform for mapping the biological architecture of resilience.

Atlas models the inflammatory networks that shape aging, recovery, chronic disease, and human performance. It identifies the molecular pathways driving those processes and generates therapeutic combinations designed to restore balance through earlier, safer, and more complete inflammation resolution.

Rather than discovering medicines one disease at a time, Atlas is designed to generate therapeutic opportunities from a shared biological framework.

One platform.

Multiple programs.

Compounding value while accelerating scale.

FROM DISCOVERY ENGINE TO PLATFORM COMPANY

Atlas is more than a discovery tool. It is the foundation of a growing computational platform designed to identify, evaluate, develop, and steward resilience therapeutics across multiple therapeutic categories.

As the platform evolves, advanced AI-driven systems will help guide everything from candidate generation and portfolio strategy to biomarker development and clinical translation—expanding Sen-Jam's ability to discover, protect, and advance new therapeutic opportunities.

Our ambition is not simply to develop individual medicines.

It is to build the defining platform for resilience therapeutics.

WE SAID WE WOULD. WE DID.

The strongest platforms are built on execution.

Over the past year, Sen-Jam has continued to strengthen both its therapeutic portfolio and the foundation of its computational discovery platform.

✓ Advanced several independent clinical programs with validating analyses across two differentiated Phase 2 Trials, interrogating the data for common biological insight with additional bloodwork analyses is actively underway.

✓ Repositioned Sen-Jam as a computational drug discovery platform that develops therapeutics

✓ Advanced Atlas from concept to active development, grounded in clinical and biomarker data

✓ Submitted SJP-001 for FDA End-of-Phase 2 review

✓ Expanded and protected our Biology of Resilience intellectual property estate

✓ Established NLR as a cross-program resilience biomarker

✓ Secured strategic partnerships with TASK Clinical Research and KVK-Tech

✓ Continued advancing a growing portfolio of resilience-first therapeutic programs

This raise is not funding an idea.

It is accelerating a platform already in motion.

FROM PLATFORM TO PROOF

A discovery platform is only valuable if it produces results.

Sen-Jam's resilience-first framework has already generated multiple therapeutic programs differentiated and demonstrating clinical validation across independent studies.

ONE BIOLOGY. MANY THERAPEUTIC OPPORTUNITIES.

Inflammation shapes aging, recovery, chronic disease, and human performance.

By restoring immune balance early in the inflammatory response, Sen-Jam is building a platform designed to preserve resilience across diverse conditions and therapeutic settings—without immunosuppression.

What begins as a shared biological framework becomes a growing portfolio of therapeutic opportunities.

Active Clinical Pipeline of Assets

Atlas-Derived Opportunities

1. Cardiometabolic Health
2. Neuroinflammation
3. Fibrosis & Tissue Repair
4. Healthy Aging & Longevity
5. Additional Undisclosed Programs

A growing portfolio of resilience therapeutics.

LEAD PROGRAMS ADVANCING

What began as a search for better ways to resolve inflammation has evolved into a growing portfolio of resilience-first therapeutics. These lead programs span recovery, respiratory health, addiction medicine, chronic inflammatory disease, and biomarker development—demonstrating the breadth of a platform built on shared biology.

Our lead assets continue to pave the way for a massive acceleration and adoption of prevention-minded medicines that insightfully address the biology of resilience to usher in a new era of longevity. Sen-Jam is proud to be among the first to unlock this paradigm shift.

WHAT THIS RAISE ACCELERATES

We believe the future of medicine lies in understanding and preserving resilience before disease emerges.

This raise is designed to accelerate that future.

01 — Expand the Inflammation Atlas

Advance our AI-powered discovery platform and continue building the computational foundation for resilience therapeutics.

02 — Advance Lead Programs

Progress our clinical portfolio of differentiated indications and assets while continuing to generate new therapeutic opportunities from a shared biological framework and unique therapeutic logic.

03 — Strengthen the Platform

Expand our biomarker, intellectual property, regulatory, and strategic partnership infrastructure to support long-term growth.

This is not funding a single asset.

It is accelerating a platform designed to generate many.

YOUR INVITATION

A future where resilience is measured, preserved, and protected is no longer a distant vision.

It's the future we're building.

We invite you to be part of it at this very special moment.

Schedule a call with CEO Jim Iversen to discuss the opportunity and learn more about Sen-Jam's platform, pipeline, and vision.

And be sure to watch for invitations to our upcoming Investor Town Hall webinars, where we'll share our latest progress and answer questions live.

Sen-Jam is building the platform designed to decode that biology, generate resilience-first therapeutics, and help people live longer, healthier lives.

We have validated the framework.

We have built the foundation.

Now we are accelerating the platform.

For investors who believe the next era of medicine begins before disease, we hope you to join us.

Together, we can build the future of resilience.

Disclosure Statement. This presentation was prepared by Sen-Jam Pharmaceutical, Inc. (the “Company”) exclusively for the benefit and internal use of the party to whom it is provided to by the Company and is the confidential information of the Company. Any further distribution or reproduction of this presentation, in whole or in part, or the divulgence of any of its contents, is unauthorized. This presentation is for discussion purposes only. No representation, express or implied, is being given by the Company as to the accuracy or completeness of the information contained herein. This presentation contains “forward-looking” statements, which involve risks, uncertainties, and assumptions. All statements, other than statements of historical fact, should be deemed forward-looking statement, and reflect the Company’s current expectations and assumptions about future events and are not guarantees of future performance. Actual results could differ materially from the Company’s current expectations because of many factors. All forward-looking statements herein reflect opinions only as of the date of this presentation.

Additional offering disclosures. The pro forma risk-adjusted NPV and any other valuation figures are internally generated, have not been independently verified, and are not guarantees of value. References to a fall-round “floor” reflect a partnership-based reference point and are not a guarantee of future valuation, financing, or returns. Investing in private, early-stage companies is highly speculative and involves the risk of total loss of capital. This material is provided to qualified investors with whom the Company has a pre-existing, substantive relationship in connection with a private offering under Regulation D, Rule 506(b); it is not an offer to sell or a solicitation of an offer to buy any security, and any offer is made only through the official offering materials.